Kiran Mazumdar Shaw, 

This year is proving to be like the last, with regulatory uncertainties continuing to dog domestic pharma, and trial approvals for clinical research still put on hold by the government. Mazumdar-Shaw decided to look outside. Biocon is setting up Asia’s largest integrated insulin-manufacturing facility in Malaysia, expected to start production by the end of FY15. Meanwhile, revenue growth stood at 16% and net profit at 25%. Elsewhere, the Biocon Academy, a centre for applied biosciences with focus on the business of science, saw its first batch graduate this year.